Amerikanische Gesellschaft für Hirudotherapie

Heparin-Induced Thrombocytopenia in a Patient with Essential Thrombocythemia: A Case Based Update

Case report published in Case Rep Hematol (2015)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportArzneimittelentwicklungKlinische StudienNoel E et al. · Case reports in hematology, 2015

Abstract

Vascular thrombosis is a common clinical feature of both essential thrombocythemia (ET) and heparin-induced thrombocytopenia (HIT). The development of HIT in a patient with ET is rare and underrecognized. We report the case of a 77-year-old woman with preexisting ET, who was admitted with acute coronary syndrome, and IV heparin was started. She was exposed to unfractionated heparin (UFH) 5 days prior to this admission. Decrease in platelet count was noted, and HIT panel was sent. Heparin was discontinued. Patient developed atrial fibrillation, and Dabigatran was started. On day three, patient also developed multiple tiny cerebral infarctions and acute right popliteal DVT. On day ten of admission, HIT panel was positive, and Dabigatran was changed to Lepirudin. Two days later, Lepirudin was also discontinued because patient developed pseudoaneurysm on the right common femoral artery at the site of cardiac catheterization access. A progressive increase in the platelet count was noted after discontinuing heparin. Physicians should be aware of the coexistence of HIT and ET, accompanied challenges of the prompt diagnosis, and initiation of appropriate treatment.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

77-year-old woman with essential thrombocythemia and HIT managed sequentially with dabigatran, then lepirudin which was discontinued due to pseudoaneurysm.

Warum dies für die Hirudotherapie relevant ist

This case report describes a 77-year-old woman with preexisting essential thrombocythemia (ET) who developed heparin-induced thrombocytopenia (HIT) after exposure to unfractionated heparin, with a positive HIT panel on day ten of admission. Lepirudin was initiated after the HIT panel returned positive but was discontinued two days later due to development of a pseudoaneurysm at the cardiac catheterization access site. While lepirudin appears in the clinical management of this case, the abstract does not describe its origin, mechanism, or any connection to leeches or hirudotherapy. No defensible leech link can be drawn from the abstract alone; this is a single case report focused on the diagnostic challenge of concurrent HIT and ET.

Zitation

Heparin-Induced Thrombocytopenia in a Patient with Essential Thrombocythemia: A Case Based Update.

Noel E et al. · Case reports in hematology, 2015

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.